Prevalence of germline T790M.

Slides:

Advertisements

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Advertisements

The expression and signaling of FGFR3 in WM cells.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

New Patient Journeys in Non-small cell lung cancer

Rearrangements of Gene A and Gene B

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Supplemental Figure 1 A B Alteration Time 1 (AF) Time 2 (AF)

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Figure 4 Example of a patients with CUP

Clonal evolution in Ewing sarcoma.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Clinical courses of patients.

Genetic landscape of salivary duct carcinoma.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Evaluation of E–R (AEs-DC/D) in NSCLC in the full model using (A) estimated covariate effects and (B) VPCs. For continuous variables in the covariate analysis,

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Frequent alterations identified and potential actionability.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Somatic mutational rates and survival analysis of IBD-CRC.

Specific up-regulation and down-regulation of immunomodulatory genes in human breast and colorectal cancers. Specific up-regulation and down-regulation.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

AMs contribute to the progression of EGFR-mutant lung adenocarcinoma.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Location of common clinically relevant mutations in EGFR

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Venn diagram for degree of overlap of 158 candidate prognostic genes.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Location of the ER mutations and frequencies per cohort.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Molecular definitions of lung adenocarcinoma subtypes.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

DFS and DSS curves according to low, intermediate, and high stromal CD8+ T-cell density in the four different cohorts; A and B, University Hospital of.

Gastric, lung, and HPV-related cancer incidence and model fits.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Validation of NAA's cancer specificity in lung cancer.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Flavopiridol inhibits rhabdoid cell survival and induces cell cycle arrest and apoptosis. Flavopiridol inhibits rhabdoid cell survival and induces cell.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

MDSC population in patient peripheral blood.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Prevalence of gBRCA1/2 mutations stratified by (A) FIGO stage, and (B) family history of cancer. Prevalence of gBRCA1/2 mutations stratified by (A) FIGO.

Presentation transcript:

Prevalence of germline T790M. Prevalence of germline T790M. A, Querying a database of 31,414 unique cancer patients with plasma NGS results, 48 (0.15%) were found to carry a germline EGFR T790M mutation. Nonsquamous non-small cell lung cancer (NSCLC) was the dominant diagnosis in these patients. B, As compared to the population prevalence of germline EGFR T790M in a reference cohort (0.008%), there is a higher prevalence in subjects with nonsquamous NSCLC (0.34%) but not in subjects with other cancers (0.03%, P = 0.06), suggesting germline EGFR T790M is a risk variant for lung cancer. *, P < 0.05. Yuebi Hu et al. Clin Cancer Res 2017;23:7351-7359 ©2017 by American Association for Cancer Research